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empower patients. It was proposed in 2001,8 yet the gov-
ernment has so far ignored the idea.
The human tissue authority should also be subject
to greater parliamentary accountability, and the licens-
ing requirements need to be more tightly defined to
avoid pointless bureaucracy. The poor wording of the
bill also needs to be addressed; seeking to create legis-
lative flexibility is not an excuse for ambiguous and
complex drafting. If the human tissue bill is not
amended then it will ultimately fail the public;
perceived improvements in the regulation of human
tissue will come at the price of less medical research,
education, and training.
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Treating malaria in Africa
Sulfadoxine-pyrimethamine may still have a future despite reports of resistance
For many years the treatment of malaria in Africahas relied on chloroquine, sulfadoxine com-bined with pyrimethamine, and quinine, with the
latter being used mainly to treat severe cases. Quinine
remains efficacious, but chloroquine and sulfadoxine-
pyrimethamine are failing, and this is leading to an
increase in mortality from malaria especially in East
Africa.1 2
Although resistance to chloroquine was first
detected on the east coast of Africa in 1977, the drug has
provided effective treatment for malaria for much of
Africa for over 20 years.3 4 Unfortunately this is unlikely
to be the case for sulfadoxine-pyrimethamine, the com-
bination adopted by several African countries as the first
line treatment for malaria when chloroquine has failed.
Systematic surveillance for resistance to malaria drugs
and the results of trials of new drugs or drug
combinations that could be used to replace chloroquine
or sulfadoxine-pyrimethamine are showing a worry-
ingly high level of resistance to sulfadoxine-
pyrimethamine across eastern and southern parts of
Africa.5 6 Resistance to sulfadoxine-pyrimethamine is
particularly severe in north east Tanzania, where clinical
failure rates of up to 50% have been described,7 but high
levels of resistance have been recorded also in parts of
Burundi, Kenya, Rwanda, and Uganda.8 Levels of resist-
ance to sulfadoxine-pyrimethamine are generally lower
in West Africa, but clinical failures are not infrequent,
and parasites carrying mutations associated with
resistance to sulfadoxine-pyrimethamine are distributed
widely across West Africa. Genetic studies show that
resistance to sulfadoxine-pyrimethamine may have
arisen in southern and eastern Africa on only a few
occasions, so these resistant strains have spread
extensively and rapidly.9 Sulfadoxine-pyrimethamine
seems to have little future as a first line antimalarial in
Africa. However, the results of a recent study by Plowe
et al (p 545) in Malawi raise the possibility that this con-
clusion may be too pessimistic.10
Malawi changed from chloroquine to sulfadoxine-
pyrimethamine as first line treatment for malaria in
1993, the first country in Africa to do so. Plowe et al
report clinical and parasitological responses of
children with uncomplicated clinical episodes of
malaria to treatment with sulfadoxine-pyrimethamine
five to nine years later (in 1998 and 2002). In 1998,
86% of children showed an adequate clinical response
14 days after treatment; four years later the response
rate was still 83%. Twenty eight days after treatment
clinical response rates were 73% and 61%, respectively,
a modest but statistically significant fall over time. Para-
sitological cure rates 14 days after treatment were 73%
in 1998 and 60% in 2002 but were much worse 28 days
after treatment—38% and 27%, respectively. Some of
the apparent 28 day failures may have been
reinfections, but even if this was the case it indicates a
high level of resistance to sulfadoxine-pyrimethamine,
as a single dose of sulfadoxine-pyrimethamine gives
up to four weeks of prophylaxis against parasites that
are sensitive to the combination.
How robust are these unexpected findings of a
relatively stable level of resistance to sulfadoxine-
pyrimethamine? The strengths of this study are that it
was carried out by the same investigators at the same
site using the same methods of analysis over the four
year study period and that the numbers of children
studied each year (82-425) were large enough to have
detected a decline in efficacy. Dropout rates were quite
high but were similar in each survey. A progressive fall
in the clinical efficacy of sulfadoxine-pyrimethamine
would have been detected had it occurred.
The results of this study from Malawi indicate that, in
contrast to the situation in other countries such as Thai-
land and South Africa, a moderate level of resistance to
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sulfadoxine-pyrimethamine can be sustained over
several years and that once resistance has emerged a
rapid decline in sensitivity is not inevitable. Why this has
happened in Malawi but not elsewhere is uncertain. The
investigators think that this may be due to the high level
of transmission of malaria in Malawi, which results in
early acquisition of immunity and many asymptomatic
infections. Because most asymptomatic infections are
not treated, only a relatively small proportion of the
parasites circulating in Malawi are exposed to an
antimalarial at any one time. This contrasts with the situ-
ation in areas where transmission is low, such as
Thailand, where nearly all infections cause symptoms
and are treated, thus providing any resistant parasites
with a strong survival advantage. Although considera-
tions of this kind could explain why resistance seems to
have developed more slowly in Malawi than in South
East Asia, it does not account for the rapid spread of
resistance to sulfadoxine-pyrimethamine in parts of East
Africa where the level of transmission is as high as, or
higher than, in Malawi.
Although the findings from this study are better
than might have been expected, they should not
induce complacency about the use of sulfadoxine-
pyrimethamine for the treatment of malaria in Africa.
Clinical and parasitological failure rates 28 days after
treatment of 20% and 70% are not satisfactory, and
many of the children with parasitaemia on day 28 will
subsequently develop a clinical attack. If these findings
are representative of the situation in other parts of
Malawi a further change in treatment policy is needed.
The results of this study should not be used to justify a
switch to monotherapy with sulfadoxine-
pyrimethamine by countries in Africa contemplating a
change from chloroquine. Strong evidence now exists
to support a change to combination therapy with two
or more drugs, each of which is highly effective
locally.11 Malawi has been fortunate to obtain 10 years
of effective use from sulfadoxine-pyrimethamine;
other countries in Africa are unlikely to be as fortunate.
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What’s the E for EBM?
Theme issue will question the evidence for evidence based medicine
Interest in evidence based medicine has grownexponentially from one Medline citation in 1992to more than 13 000 in 2004. Professional organi-
sations and training programmes for healthcare
professionals have moved from whether to teach
evidence based medicine to how to teach it, resulting in
an explosion in the number of courses, workshops, and
seminars offered in this practice. Reports describing
evidence based rejuvenations of traditional edu-
cational events are burgeoning, and case reports and a
survey of residency programmes have concluded that
some of the determinants of continuing high
attendance at postgraduate journal clubs include the
teaching of critical appraisal skills and emphasising the
primary literature (and not surprisingly, providing free
food).1 2 Familiarity with its terminology has extended
into the popular press, as evidenced by a recent article
in the Times describing the number needed to treat.3
But all this leads to the question, “What’s the E for
EBM?”
Discussion about the practice of evidence based
medicine naturally engenders negative and positive
reactions from clinicians. Some of the criticisms focus on
misunderstandings and misperceptions of evidence
based medicine such as the concerns that it ignores
patients’ values and preferences and promotes a
cookbook approach.4 But this debate has highlighted
limitations unique to the practice of evidence based
medicine that must be considered. For example, the dif-
ficulty of developing new skills in seeking and appraising
evidence cannot be underestimated.Moreover, the need
to develop and apply these skills within the time
constraints of our clinical practice must be addressed.
The body of evidence relating to the impact of evi-
dence based medicine on healthcare professionals
ranges from systematic reviews of training in the skills
of evidence based medicine to qualitative research
describing the experience of evidence based medicine
practitioners.5 6 However, studies of the effect of teach-
ing and practising evidence based medicine are
challenging to conduct. In many studies, the interven-
tion has been difficult to define. What the appropriate
“dose” or “formulation” should be is unclear. Some
studies use an approach to clinical practice while
others use training in one of the discrete microskills of
evidence based medicine such as searching Medline or
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